Cardiac-specific YAP activation improves cardiac function and survival in an experimental murine MI model

Z Lin, A von Gise, P Zhou, F Gu, Q Ma, J Jiang… - Circulation …, 2014 - Am Heart Assoc
Z Lin, A von Gise, P Zhou, F Gu, Q Ma, J Jiang, AL Yau, JN Buck, KA Gouin, PRR van Gorp…
Circulation research, 2014Am Heart Assoc
Rationale: Yes-associated protein (YAP), the terminal effector of the Hippo signaling
pathway, is crucial for regulating embryonic cardiomyocyte proliferation. Objective: We
hypothesized that YAP activation after myocardial infarction (MI) would preserve cardiac
function and improve survival. Methods and Results: We used a cardiac-specific, inducible
expression system to activate YAP in adult mouse heart. Activation of YAP in adult heart
promoted cardiomyocyte proliferation and did not deleteriously affect heart function …
Rationale
Yes-associated protein (YAP), the terminal effector of the Hippo signaling pathway, is crucial for regulating embryonic cardiomyocyte proliferation.
Objective
We hypothesized that YAP activation after myocardial infarction (MI) would preserve cardiac function and improve survival.
Methods and Results
We used a cardiac-specific, inducible expression system to activate YAP in adult mouse heart. Activation of YAP in adult heart promoted cardiomyocyte proliferation and did not deleteriously affect heart function. Furthermore, YAP activation after MI preserved heart function and reduced infarct size. Using adeno-associated virus subtype 9 (AAV9) as a delivery vector, we expressed human YAP (hYAP) in the adult murine myocardium immediately after MI. We found that AAV9:hYAP significantly improved cardiac function and mouse survival. AAV9:hYAP did not exert its salutary effects by reducing cardiomyocyte apoptosis. Rather, AAV9:hYAP stimulated adult cardiomyocyte proliferation. Gene expression profiling indicated that AAV9:hYAP stimulated expression of cell cycle genes and promoted a less mature cardiac gene expression signature.
Conclusions
Cardiac-specific YAP activation after MI mitigated myocardial injury, improved cardiac function, and enhanced survival. These findings suggest that therapeutic activation of YAP or its downstream targets, potentially through AAV-mediated gene therapy, may be a strategy to improve outcome after MI.
Am Heart Assoc